Reuters logo
BRIEF-Esperion announces FDA confirmation to approval for an LDL-C lowering indication for bempedoic acid
March 20, 2017 / 11:38 AM / in 7 months

BRIEF-Esperion announces FDA confirmation to approval for an LDL-C lowering indication for bempedoic acid

March 20 (Reuters) - Esperion Therapeutics Inc

* Esperion announces fda confirmation regarding regulatory pathway to approval for an ldl-c lowering indication for bempedoic acid

* Esperion therapeutics inc - on track to submit nda for an ldl-c lowering indication by 1h 2019

* Esperion therapeutics- remain focused on completing global pivotal phase 3 program for bempedoic acid

* Esperion therapeutics inc - remain focused on reporting top-line results from our long-term safety and tolerability study by q2 2018

* Esperion therapeutics- expects to submit nda for cardiovascular disease risk reduction indication to fda, marketing authorization application to ema by 2022 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below